Posts in Convegni

  • Home
  • Category "Convegni"
  • (Page 5)

MDM2 309 single nucleotide polymorphisms (SNP) and clinical outcome in patients with locally advanced squamous cell carcinoma of head and neck (LASCCHN)

Posted on 17 dicembre 2014

Vivenza D, Natoli G, Gasco M, Monteverde M, Lattanzio L, Colantonio I, Comino A, Crook T,  Merlano M, Lo Nigro C: “MDM2 309 single nucleotide polymorphisms (SNP) and clinical outcome in patients with locally advanced squamous cell carcinoma of head and neck (LASCCHN)”, 53 Congresso Nazionale della Società Italiana di Cancerologia (SIC), Torino, 19-22 ottobre […]

Methylation in NT5E CpG island influences metastatic site specificity in melanoma

Posted on

Lo Nigro C, Wang H, Lattanzio L, Monteverde M, Occelli M, Matin R, Harwood C, Syed N, Hatzimichael E, Fleming C, Merlano M, Proby C and Crook T: “Methylation in NT5E CpG island influences metastatic site specificity in melanoma”, XVII IMI (Italian Melanoma Intergroup) Annual Congress, Milano, 2-5 ottobre 2011

The prolyl-3-hydroxylases (P3H) and P3H-related genes CRTAP and SC65 are novel transcriptionally silenced genes in Burkitt’s lymphomas

Posted on

Lo Nigro C, Syed N, Lattanzio L, Dasoula A, Vivenza D, Montverde M, Schmid P, Hatzimichael E, CrookT: “The prolyl-3-hydroxylases (P3H) and P3H-related genes CRTAP and SC65 are novel transcriptionally silenced genes in Burkitt’s lymphomas”, 36th ESMO Congress,  Stoccolma, Svezia, 23-27 settembre 2011.

The prolyl-3-hydroxylases (P3H) and P3H-related genes CRTAP and SC65 are novel transcriptionally silenced genes in non-Hodgkin lymphomas

Posted on 9 dicembre 2014

Lo Nigro C, Syed N, Lattanzio L, Dasoula A, Vivenza D, Montverde M, Schmid P, Hatzimichael E, CrookT: “The prolyl-3-hydroxylases (P3H) and P3H-related genes CRTAP and SC65 are novel transcriptionally silenced genes in non-Hodgkin lymphomas”, 2011 IRCC International Conference on Molecular Clinical Oncology, Candiolo (TO), 26-28 maggio 2011

MDM2 309 single nucleotide polymorphisms (SNP) and clinical outcome in patients with advanced squamous cell carcinoma of head and neck (SCCHN)

Posted on

Gasco M, Vivenza D, Monteverde M, Lattanzio L, Colantonio I, Natoli G, Miraglio E, Comino A, Syed N, Crook T, Merlano M, Lo Nigro C: “MDM2 309 single nucleotide polymorphisms (SNP) and clinical outcome in patients with advanced squamous cell carcinoma of head and neck (SCCHN)”, Annual Meeting ASCO, Chicago (IL), USA, 3-7 giugno 20

Methylation of NT5E gene is common in metastatic breast cancer

Posted on

Lo Nigro C, Lattanzio L, Monteverde M, Syed N, Thompson A, Garrone O, Cavicchioli F, Tornissi F, Comino A, McHugh A,  Roncaroli F, Palmieri C , Schmid P, Merlano M, Crook T: “Methylation of NT5E gene is common in metastatic breast cancer”, Annaul Meeting ASCO, Chicago (IL), USA, 3-7 giugno 201

Genetic and epigenetic determinants of outcome in locally advanced head-and-neck cancer

Posted on

Lo Nigro C, Gasco M, Vivenza D, Lattanzio L, Monteverde M, Comino A, Syed N, Crook T, Merlano M: “Genetic and epigenetic determinants of outcome in locally advanced head-and-neck cancer”, 102nd AACR Annual Meeting,  Orlando (FL), USA, 2-6 aprile 2

Leprecan Like 1 (Leprel1) a prolyl-3-hydroxylase, but not Leprel2 or Leprecan, is a novel target for epigenetic silencing in multiple myeloma

Posted on

Hatzimichael E, Xirofotou E, Dasoula A, Lo Nigro C, Lattanzio L, Merlano M, Dranitsaris G,  Bourantas K, Crook T: “Leprecan Like 1 (Leprel1) a prolyl-3-hydroxylase, but not Leprel2 or Leprecan, is a novel target for epigenetic silencing in multiple myeloma”. 52nd ASH Annual Meeting,  Orlando (FL), USA, 4-7 dicembre 2010.

Leprecan Like 1 (Leprel1) a prolyl-3-hydroxylase, but not Leprel2 or Leprecan, is a novel target for epigenetic silencing in multiple myeloma

Posted on

Hatzimichael E, Dasoula A, Lo Nigro C, Lattanzio L, Syed N, Merlano M, Bourantas K, Crook T: “Leprecan Like 1 (Leprel1) a prolyl-3-hydroxylase, but not Leprel2 or Leprecan, is a novel target for epigenetic silencing in multiple myeloma”. Lymphoma and Myeloma Meeting, NYC, USA, 21-23 ottobre 201

P3H collagen prolyl hydroxylases are tissue selective tumour suppressors

Posted on

Lo Nigro C, Lattanzio L, Syed N, Monteverde M, Dasoula A, Hatzimichael E, Papoudou-Bai A, Schmid P, Merlano M, Crook T: “P3H collagen prolyl hydroxylases are tissue selective tumour suppressors”, 35th ESMO Congress, Milano, 8-12 ottobre 2010 (poster discussion).